Erlotinib (ERL), an inhibitor of the epidermal growth-factor receptor (EGFR) tyrosine kinase, was approved by the US Food and Drug Administration (FDA) for the treatment of local or advanced metastatic non-small cell lung cancer and pancreatic cancer in 2004 [25]. The gene discussed is EGFR; the disease is familial pancreatic carcinoma.